Corrigendum: Epigenetic inactivation of the miR-34a in hematological malignancies. [Carcinogenesis, 31, 4, (2010), (745-750)] Doi: 10.1093/carcin/bgq033;Epigenetic inactivation of the miR-34a in hematological malignancies

Carcinogenesis

Volumn 31, Issue 4, 2010, Pages 745-750

  Chim, C S ^a   Wong, K Y ^a   Qi, Y ^a   Loong, F ^a   Lam, W L ^b   Wong, L G ^c   Jin, D Y ^a   Costello, J F ^d   Liang, R ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b PRINCESS MARGARET HOSPITAL   (Hong Kong)

^c TUEN MUN HOSPITAL   (Hong Kong)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MIRN34 MICRORNA, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE INACTIVATION; HEMATOLOGIC MALIGNANCY; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NK T CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMOTER REGION; RNA TRANSCRIPTION; BLOOD DISEASE; DNA METHYLATION; DRUG ANTAGONISM; GENETIC EPIGENESIS; GENETICS; HETEROZYGOSITY LOSS; MIDDLE AGED; POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, P53; HEMATOLOGIC NEOPLASMS; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICRORNAS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC;

EID: 77950910741     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu196     Document Type: Erratum

References (35)

1. Chim, C.S. et al. (2002) Hypermethylation of gene promoters in hematological neoplasia. Hematol. Oncol., 20, 167-176.
2. Herman, J.G. et al. (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med., 349, 2042-2054.
3. Chim, C.S. et al. (2001) Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J. Clin. Oncol., 19, 2033-2040.
4. Chim, C.S. et al. (2003) Aberrant gene promoter methylation in acute promyelocytic leukaemia: profile and prognostic significance. Br. J. Haematol., 122, 571-578.
5. Chim, C.S. et al. (2008) Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach. Clin. lymphoma myeloma, 8, 331-339.
6. Chim, C.S. et al. (2007) Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma. Leukemia, 21, 2527-2536.
7. Chim, C.S. et al. (2007) Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J. Clin. Pathol., 60, 664-669.
8. Chim, C.S. et al. (2004) SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood, 103, 4630-4635.
9. Chim, C.S. et al. (2004) Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias. Ann. Hematol., 83, 527-532.
10. Chim, C.S. et al. (2003) Disruption of INK4//CDK//Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia, 17, 2533-2535.
11. Chim, C.S. et al. (2006) Aberrant gene promoter methylation marking disease progression in multiple myeloma. Leukemia, 20, 1190-1192.
12. Calin, G.A. et al. (2006) MicroRNA signatures in human cancers. Nat. Rev. Cancer, 6, 857-866.
13. Peller, S. et al. (2003) TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum. Mutat., 21, 277-284.
14. Lodygin, D. et al. (2008) Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle, 7, 2591-2600.
15. Bennett, J.M. et al. (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br. J. Haematol., 33, 451-458.
16. (1988) Second MIC Cooperative Study Group. Morphologic, immunologic and cytogenetic (MIC) working classification of the acute myeloid leukaemias. Br. J. Haematol., 68, 487-494.
17. Hallek, M. et al. (2008) International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
18. Swerdlow, S.H. et al. (2008) WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th edn. International Agency for Research on Cancer, Lyon.
19. Chang, T.C. et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell, 26, 745-752.
20. Tarasov, V. et al. (2007) Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle, 6, 1586-1593.
21. Lujambio, A. et al. (2007) CpG hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle, 6, 1455-1459.
22. Chim, C.S. et al. (2004) Primary nasal natural killer cell lymphoma: longterm treatment outcome and relationship with the International Prognostic Index. Blood, 103, 216-21.
23. Siu, L.L. et al. (2003) Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas. Br. J. Haematol., 122, 70-77.
24. Zenz, T. et al. (2008) Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway. Cell Cycle, 7, 3810-3814.
25. Soussi, T. et al. (2000) p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum. Mutat., 15, 105-113.
26. Döhner, H. et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med., 343, 1910-1916.
27. Chim, C.S. et al. (2006) Frequent DAP kinase but not p14 or Apaf-1 hypermethylation in B-cell chronic lymphocytic leukemia. J. Hum. Genet., 51, 832-838.
28. Toyota, M. et al. (2008) Epigenetic silencing of MicroRNA-34b/c and B-Cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res., 68, 4123-4132.
29. Knudson, A.G. (1997) Karnofsky Memorial Lecture. Hereditary cancer: theme and variations. J. Clin. Oncol., 15, 3280-3287.
30. Ragnarsson, G. et al. (1999) Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br. J. Cancer, 79, 1468-1474.
31. Caren, H. et al. (2007) Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours. Br. J. Cancer, 97, 1416-1424.
32. Mori, N. et al. (1998) Chromosome band 1p36 contains a putative tumor suppressor gene important in the evolution of chronic myelocytic leukemia. Blood, 92, 3405-3409.
33. Naoki, M. et al. (2003) Progression of myelodysplastic syndrome: allelic loss on chromosomal arm 1p. Br. J. Haematol., 122, 226-230.
34. Beatriz, M.-D. et al. (2002) Frequent inactivation of the p73 gene by abnormal methylation or LOH in non-Hodgkin's lymphomas. Int. J. Cancer, 102, 15-19.
35. Candeias, M.M. et al. (2006) Expression of p53 and p53//47 are controlled by alternative mechanisms of messenger RNA translation initiation. Oncogene, 25, 6936-6947.